HENLIUS

2696
44.8406.82% ( -3.280 )
Delay Closed: Nov 16, 16:08:11

Overview

HENLIUS (2696)

Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic disea...

Open
48.300
High
49.460
Low
43.020
Prev. Close
48.120
Volume
1.84M
Turnover
81.96M
Avg Price
44.520
Bid/Ask Ratio
83.84%
Amplitude
13.38%
52wk High
87.100
Volume Ratio
2.95
Turnover Ratio
0.53%
52wk Low
43.020
HK Mkt Cap
15.60B
Market CapHKD
24.45B
P/ETTM
24.48
P/EDynamic
24.67
P/EStatic
--
EPSTTM
1.83
EPSDynamic
1.82
EPSStatic
--
BVPS
9.58
P/B
4.68
HK Shares
347.88M
Dividend YieldTTM
--
DividendTTM
--
Shares
545.30M
Min lot size
100
Currency
HKD

HENLIUS Analyst Rating

View more

Forecast & Rating

Nov 12, 2026
Price forecast
HK$100.44123.99%
Forecast & RatingStrong buy
9analysts
  • Strong buy88.89%
  • Buy11.11%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    Henlius dropped 6.3% to HK$45.08 from HK$48.12, with an early high near HK$48.20 giving way to a 10:53 BJ low of HK$43.14, just above the 52-week low of HK$43.02, as the recent board reshuffle overshadowed the addition of HANSIZHUANG and FUTUONING to the 2026 NRDL. The session recorded HK$80.3 million of turnover on 1.80 million shares. The intraday range of HK$5.06, about 10.5% from high to low, underscores the scale of the reversal. Fundamentals remain solid: Q2 revenue rose 34.15% year on year to HK$2.07 billion, net profit gained 16.3% to HK$248.6 million, EPS reached HK$0.4562 for a 16.01% increase, and ROE stood at 18.97%. Even so, the stock trades below its MA20 of HK$49.67 and MA60 of HK$57.29, is down 23.07% year to date, sits 48.24% below the 52-week high of HK$87.10, and carries a 24.62x PE and 4.70x PB. Positive ASTRIDE U.S. bridging data for serplulimab plus chemotherapy in ES-SCLC did not arrest the decline, though the NRDL inclusion still contrasts with the price action. The 52-week low was set only a day earlier, on 2026-11-15.

  2. Nov, 13

    Henlius fell 3.12% to HK$48.42 after an early probe to HK$50.00 faded, sliding to HK$47.46 at 13:25 BJ before closing near the afternoon open on HK$22.46 million turnover. Guotai Haitong reiterated a Buy rating, positive ASTRIDE US bridging-study results for serplulimab plus chemotherapy in first-line ES-SCLC and Australian Phase 1 clearance for HLX109 were set against the board's proposal to lift the 2026 HLX01 collaboration cap to RMB714 million. Price sits below the MA20 of HK$50.00 and MA60 of HK$57.72, down 17.37% YTD and 44.41% from the 52-week high of HK$87.10, though still 6.42% above the 2 November low of HK$45.50. Q2 revenue of HK$2.07 billion grew 34.15% yoy with net profit up 16.3% to HK$249 million and ROE at 18.97%, against PE of 26.44x and PB of 5.05x, so today's pullback ran against that backdrop; licensing and trial milestones remain the swing factor.

  3. Nov, 9

    Hong Kong biopharma names rallied across the board and Henlius staged a spike-and-fade: the stock touched HK$52.00 at 09:35 BJ, roughly 6% above the HK$49.02 prior close, then bled lower through the afternoon session to HK$49.68 and last printed near HK$49.78. The morning pop traced to Australian TGA clearance for a Phase 1 trial of HLX109, an IL1RAP-targeting antibody for generalized pustular psoriasis, layered on positive ASTRIDE US bridging results for serplulimab plus chemotherapy in first-line ES-SCLC. Fundamentals still outrun the tape, with Q2 2026 revenue up 34.15% yoy, net profit up 16.3% yoy and ROE at 18.97%, yet the price sits below both the MA20 of HK$50.47 and the MA60 of HK$58.90, down 15.05% year-to-date and 42.85% beneath the HK$87.10 52-week high. Though at 27.18x PE and 5.19x PB, further re-rating still hinges on pipeline delivery.

  4. Nov, 4

    Henlius staged a dip-then-rebound session, closing at HK$48.14 for a 3.70% gain after opening at HK$47.24, sliding to HK$46.50 in the morning and then pushing up to HK$49.98 in the afternoon on 1.493 million shares worth about HK$72.9 million. The driver was the positive ASTRIDE U.S. bridging study of serplulimab (H drug) with chemotherapy in first-line extensive-stage small cell lung cancer, selected for an ESMO oral presentation, alongside GIC adding 592,000 shares at HK$52.5738 and CEO Zhu Jun buying 20,000 shares at HK$49.92. Q2 2026 revenue reached HK$2.072 billion, up 34.15% year on year, with net profit of HK$248.6 million up 16.3%. Yet the shares remain below the MA20 of HK$50.91 and the MA60 of HK$59.87, down 17.85% year to date and 44.73% below the April 7 52-week high of HK$87.10, only 5.8% above the November 2 low of HK$45.50, while profit growth of 16.3% trails revenue growth.

  5. Oct, 22

    2696.HK reversed an early gain and closed at HK$49.42, down about 8%, after touching HK$53.85 in the morning session when the ESMO congress selected the US bridging ASTRIDE study of its H drug for an oral presentation, then sliding to an intraday low of HK$48.86 in the afternoon. Fundamentals contrast with the tape: Q2 2026 revenue reached HK$2.07bn, up 34.15% yoy, with net profit of HK$248.6m up 16.3%, EPS of HK$0.4562 up 16.01% and ROE near 18.97%. The stock sits 15.67% lower year-to-date, 43.26% below its 52-week high of HK$87.10 and just 3.78% above the 52-week low of HK$47.62, while trading below both its MA20 of HK$54.74 and MA60 of HK$61.52. CITIC Securities maintained its Buy rating with a HK$122 target, and CEO Zhu Jun added 20,000 shares at HK$49.92 each. Volume was light at 838,300 shares, a 0.24% turnover rate, with PE at 26.99x.

News